Trial Profile
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs Birtamimab (Primary)
- Indications Amyloid light-chain amyloidosis
- Focus Registrational; Therapeutic Use
- Acronyms PRONTO
- Sponsors Prothena
- 12 Dec 2023 Results of pooled analysis of phase 1-3 studies ((NCT01707264) with open-label extension (OLE; NCT02613182) and 2 RCTs (Phase 2 PRONTO with OLE [NCT03154047] and Phase 3 VITAL)) assessing safety from birtamimab, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 10 Oct 2020 This trial is completed in UK (Global End Date: 05 Mar 2018), according to European Clinical Trials Database record.
- 23 Apr 2018 Results presented in a Prothena media release.